Rapt Therapeutics $RAPT Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Rapt Therapeutics by 29.7%, owning 342,190 shares after selling 144,758 shares in the 1st quarter.
• Rapt Therapeutics has received mixed ratings from analysts, with one strong buy, three buy ratings, and five hold ratings, and an average target price of $23.50.
• Shares of Rapt Therapeutics are currently trading at $26.38, up 7.9%, with a market capitalization of $436.33 million.

Goldman Sachs Group Inc. decreased its holdings in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 29.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,190 shares of the company's stock after selling 144,758 shares during the period. Goldman Sachs Group Inc. owned about 2.07% of Rapt Therapeutics worth $417,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Simplicity Wealth LLC acquired a new stake in shares of Rapt Therapeutics during the first quarter worth $25,000. Invesco Ltd. raised its holdings in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock worth $72,000 after purchasing an additional 47,391 shares during the period. Comerica Bank raised its holdings in shares of Rapt Therapeutics by 53.9% during the first quarter. Comerica Bank now owns 89,327 shares of the company's stock worth $109,000 after purchasing an additional 31,287 shares during the period. Callan Family Office LLC raised its holdings in shares of Rapt Therapeutics by 53.9% during the first quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock worth $109,000 after purchasing an additional 31,287 shares during the period. Finally, Checkpoint Capital L.P. acquired a new stake in shares of Rapt Therapeutics during the first quarter worth $134,000. 99.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RAPT has been the topic of a number of research reports. Zacks Research cut shares of Rapt Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, August 22nd. Lifesci Capital raised shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price objective on the stock in a report on Tuesday, July 22nd. UBS Group set a $9.00 price objective on shares of Rapt Therapeutics and gave the stock a "neutral" rating in a report on Tuesday, August 12th. HC Wainwright increased their price objective on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a report on Thursday, July 10th. Finally, Leerink Partners raised shares of Rapt Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $16.00 to $37.00 in a report on Friday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $23.50.

Rapt Therapeutics Trading Up 7.9%

RAPT stock opened at $26.38 on Friday. The firm has a 50-day moving average of $13.59 and a two-hundred day moving average of $10.06. The firm has a market capitalization of $436.33 million, a PE ratio of -1.86 and a beta of -0.10. Rapt Therapeutics has a one year low of $5.67 and a one year high of $27.00.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). On average, equities research analysts anticipate that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.